A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Study Identifier
CVL-871-2001
CT.gov Identifier
NCT04958031
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Results Available

Protocol
Available Language(s): English
Download document(s)
Statistical Analysis Plan
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Depression
    • Study Drug
  • CVL-871 1.0 mg
  • CVL-871 3.0 mg
  • Placebo
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    50 - 85 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Meets diagnostic criteria for apathy in neurocognitive disorders * Clinically significant apathy * Mild to Moderate Dementia (AD, FTD, VAD, or DLB)
    Exclusion Criteria:
    * Other significant psychiatric disorder(s) * Other neurological disorders (other than AD, FTD, VAD, or DLB)

    Protocol Summary

    The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.

    Study Locations

    Location
    Status
    Location
    Scottsdale, Arizona
    Scottsdale, Arizona, United States, 85258
    Status
    Not applicable
    Location
    Little Rock, Arkansas
    Little Rock, Arkansas, United States, 72114
    Status
    Not applicable
    Location
    San Diego, California
    San Diego, California, United States, 92123
    Status
    Not applicable
    Location
    Santa Ana, California
    Santa Ana, California, United States, 92705
    Status
    Not applicable
    Location
    New Haven, Connecticut
    New Haven, Connecticut, United States, 06510
    Status
    Not applicable
    Location
    Delray Beach, Florida
    Delray Beach, Florida, United States, 33445
    Status
    Not applicable
    Showing {first} - {last} of {total} Results